The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial

Combining a glucagon-like peptide-1 receptor agonist (GLP1-RA) with basal insulin is an emerging option when initiating injectable therapy in longstanding type 2 diabetes (T2DM). Recognizing that short-term insulin therapy can improve beta-cell function and induce glycemic remission in early T2DM, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Retnakaran, Ravi, Ye, Chang, Emery, Alexandra, Kramer, Caroline K., Zinman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573864/
https://www.ncbi.nlm.nih.gov/pubmed/36244997
http://dx.doi.org/10.1038/s41467-022-33867-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573864/
https://www.ncbi.nlm.nih.gov/pubmed/36244997
http://dx.doi.org/10.1038/s41467-022-33867-9

Ejemplares similares